EL7.AI
StocksMedium•29 July 2026•
1 min read

Morgan Stanley Hikes Centene Price Target as Company Raises 2026 Profit Guidance

Key Facts

1Centene raised its 2026 adjusted EPS guidance to over $4.80 following strong Q2 results.
2Morgan Stanley raised its price target for Centene to $66.00 from $57.00.
3The company achieved a Commercial Health Benefit Ratio (HBR) of 79.2%, reflecting improved cost management efficiency.

Reflecting growing optimism in the U.S. healthcare sector, Centene Corporation has raised its full-year 2026 adjusted earnings per share (EPS) guidance to exceed $4.80. This upward revision follows a robust second quarter where the company reported an adjusted EPS of $2.51, driven by strong revenue and profit growth. According to analyst reports, the improved outlook is largely attributed to enhanced cost management within its Marketplace segment.

In response to these financial milestones, Morgan Stanley raised its price target for Centene to $66.00 from $57.00. The company's operational efficiency was further evidenced by a Commercial Health Benefit Ratio (HBR) of 79.2%, which indicates improved management of medical spending relative to premiums. Per market and analyst data, this guidance hike signals that full-year profitability is expected to surpass previous market anticipations.

Investors should monitor the company's ability to maintain its leading cost structure in upcoming quarters. While no direct corporate catalysts are listed in the immediate 7-day calendar, broader market sentiment will continue to influence large-cap healthcare valuations.